Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target

17 Jan 2014

Abstract excerpt

Multiple myeloma (MM) is an incurable haematological malignancy characterised by the proliferation of mature antibody-secreting plasma B cells in the bone marrow. MM can arise from initiating translocations, of which the musculoaponeurotic fibrosarcoma (MAF) family is implicated in ∼5%. MMs bearing Maf translocations are of poor prognosis. These translocations are associated with elevated Maf expression,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Peptidase Inhibition and Analysis
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24442204
DOI: 10.1038/bcj.2013.67

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic targetPMID 24442204Read ↗

MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myelomaSemantic proximity Read ↗

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myelomaSemantic proximity Read ↗

Bruton’s Tyrosine Kinase Targeting in Multiple MyelomaSemantic proximity Read ↗

Aurora kinase A is a target of Wnt/β-catenin involved in multiple myeloma disease progressionSemantic proximity Read ↗

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expressionSemantic proximity Read ↗

The EGFL7-ITGB3-KLF2 axis enhances survival of multiple myeloma in preclinical modelsSemantic proximity Read ↗

Multiple myeloma: lusting for NF-kappaB.Semantic proximity Read ↗

Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myelomaSemantic proximity Read ↗

Overcoming bortezomib resistance in multiple myelomaSemantic proximity Read ↗

Novel Interleukin-6 Inducible Gene PDZ-Binding Kinase Promotes Tumor Growth of Multiple Myeloma CellsSemantic proximity Read ↗

POZ Domain Transcription Factor Kaiso is a Downstream Effector of STAT1 for Multiple Myeloma Cell Survival and is also essential for Anoikis Resistance of Metastatic Solid TumorsSemantic proximity Read ↗

SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.